Phase 2 trial of tremelimumab in patients with metastatic urothelial cancer previously treated with programmed death 1/programmed death ligand 1 blockade.
Saved in:
| Title: | Phase 2 trial of tremelimumab in patients with metastatic urothelial cancer previously treated with programmed death 1/programmed death ligand 1 blockade. |
|---|---|
| Authors: | Miller EJ; Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, New York, New York, USA., Rose TL; Division of Oncology, University of North Carolina, Chapel Hill, North Carolina, USA., Maughan BL; Division of Hematology and Medical Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA., Milowsky MI; Division of Oncology, University of North Carolina, Chapel Hill, North Carolina, USA., Bilen MA; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia, USA.; Winship Cancer Institute of Emory University, Atlanta, Georgia, USA., Carthon BC; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia, USA.; Winship Cancer Institute of Emory University, Atlanta, Georgia, USA., Gao X; Department of Internal Medicine, Division of Hematology/Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA., Rapisuwon S; Division of Hematology and Medical Oncology, Georgetown Lombardi Comprehensive Cancer Center, Medstar Georgetown University Hospital, Washington, DC, USA., Zhao Q; Department of Biostatistics and Medical Informatics, University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, USA., Yu M; Department of Biostatistics and Medical Informatics, University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, USA., Agarwal N; Division of Hematology and Medical Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA., Galsky MD; Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, New York, New York, USA. |
| Source: | Cancer [Cancer] 2024 May 01; Vol. 130 (9), pp. 1642-1649. Date of Electronic Publication: 2024 Jan 05. |
| Publication Type: | Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1097-0142 |
|---|---|
| DOI: | 10.1002/cncr.35179 |
